Literature DB >> 28229976

Immune modulation by dendritic-cell-based cancer vaccines.

Chaitanya Kumar1, Sakshi Kohli, Poonamalle Parthasarathy Bapsy, Ashok Kumar Vaid, Minish Jain, Venkata Sathya Suresh Attili, Bandana Sharan.   

Abstract

The interplay between host immunity and tumour cells has opened the possibility of targeting tumour cells by modulation of the human immune system. Cancer immunotherapy involves the treatment of a tumour by utilizing the recombinant human immune system components to target the pro-tumour microenvironment or by revitalizing the immune system with the ability to kill tumour cells by priming the immune cells with tumour antigens. In this review, current immunotherapy approaches to cancer with special focus on dendritic cell (DC)-based cancer vaccines are discussed. Some of the DC-based vaccines under clinical trials for various cancer types are highlighted. Establishing tumour immunity involves a plethora of immune components and pathways; hence, combining chemotherapy, radiation therapy and various arms of immunotherapy, after analysing the benefits of individual therapeutic agents, might be beneficial to the patient.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28229976     DOI： 10.1007/s12038-017-9665-x

Source DB:  PubMed          Journal:  J Biosci        ISSN： 0250-5991            Impact factor:   1.826


  112 in total

1.  Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo.

Authors:  Julien Taïeb; Koji Maruyama; Christophe Borg; Magali Terme; Laurence Zitvogel
Journal:  Blood       Date:  2004-03-01       Impact factor: 22.113

2.  Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro.

Authors:  P Correale; C Botta; M G Cusi; M T Del Vecchio; M M De Santi; G Gori Savellini; E Bestoso; S Apollinari; S Mannucci; M Marra; A Abbruzzese; A Aquino; M Turriziani; L Bonmassar; M Caraglia; P Tagliaferri
Journal:  Int J Cancer       Date:  2011-08-16       Impact factor: 7.396

Review 3.  Combining immunotherapy and targeted therapies in cancer treatment.

Authors:  Matthew Vanneman; Glenn Dranoff
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

4.  Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells.

Authors:  Joseph W Fay; A Karolina Palucka; Sophie Paczesny; Madhav Dhodapkar; Dennis A Johnston; Susan Burkeholder; Hideki Ueno; Jacques Banchereau
Journal:  Cancer Immunol Immunother       Date:  2005-12-06       Impact factor: 6.968

5.  HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ.

Authors:  Anupama Sharma; Ursula Koldovsky; Shuwen Xu; Rosemarie Mick; Robert Roses; Elizabeth Fitzpatrick; Susan Weinstein; Harvey Nisenbaum; Bruce L Levine; Kevin Fox; Paul Zhang; Gary Koski; Brian J Czerniecki
Journal:  Cancer       Date:  2012-01-17       Impact factor: 6.860

6.  A phase I clinical trial of CD1c (BDCA-1)+ dendritic cells pulsed with HLA-A*0201 peptides for immunotherapy of metastatic hormone refractory prostate cancer.

Authors:  Rebecca L Prue; Frank Vari; Kristen J Radford; Hui Tong; Melinda Y Hardy; Rachael D'Rozario; Nigel J Waterhouse; Tony Rossetti; Robert Coleman; Christopher Tracey; Hans Goossen; Vinay Gounder; Georgina Crosbie; Sonia Hancock; Stephanie Diaz-Guilas; Paul Mainwaring; Peter Swindle; Derek N J Hart
Journal:  J Immunother       Date:  2015 Feb-Mar       Impact factor: 4.456

7.  Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid malignancies, on supportive care.

Authors:  Poonamalle Parthasarathy Bapsy; Bandana Sharan; Chaitanya Kumar; Rajeev Patrick Das; Bharath Rangarajan; Minish Jain; Venkata Sathya Suresh Attili; Sundaram Subramanian; Shyam Aggarwal; Mala Srivastava; Ashok Vaid
Journal:  Cytotherapy       Date:  2014-02       Impact factor: 5.414

8.  The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.

Authors:  Junko Ozao-Choy; Ge Ma; Johnny Kao; George X Wang; Marcia Meseck; Max Sung; Myron Schwartz; Celia M Divino; Ping-Ying Pan; Shu-Hsia Chen
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

Review 9.  Immunoregulatory T cells in tumor immunity.

Authors:  Masaki Terabe; Jay A Berzofsky
Journal:  Curr Opin Immunol       Date:  2004-04       Impact factor: 7.486

10.  Gamma delta T cells provide an early source of interferon gamma in tumor immunity.

Authors:  Yunfei Gao; Wancai Yang; Meng Pan; Eileen Scully; Michael Girardi; Leonard H Augenlicht; Joe Craft; Zhinan Yin
Journal:  J Exp Med       Date:  2003-08-04       Impact factor: 14.307
View more
  3 in total

1.  Targets and Strategies for Cancer Immunoprevention.

Authors:  Nese Unver; Chirayu Mohindroo
Journal:  Methods Mol Biol       Date:  2022

2.  A Novel In Situ Dendritic Cell Vaccine Triggered by Rose Bengal Enhances Adaptive Antitumour Immunity.

Authors:  Lanlin Zhang; Jiangyuan Du; Qian Song; Chufan Zhang; Xianghua Wu
Journal:  J Immunol Res       Date:  2022-02-01       Impact factor: 4.818

3.  Murine hepatoma treatment with mature dendritic cells stimulated by Trichinella spiralis excretory/secretory products.

Authors:  Jing Ding; Xiaolei Liu; Bin Tang; Xue Bai; Yang Wang; Shicun Li; Jian Li; Mingyuan Liu; Xuelin Wang
Journal:  Parasite       Date:  2020-07-21       Impact factor: 3.000
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.